Edoxaban, Rivaroxaban or Apixaban for Cancer-Associated Venous Thromboembolism in the Real World: Insights from the COMMAND VTE Registry-2

CONCLUSIONS: The risks of recurrent VTE and all-cause death did not differ significantly among the different DOACs ; however, the risk of bleeding events could differ, with a potentially lower risk of bleeding with rivaroxaban.PMID:38684190 | DOI:10.1055/a-2316-5269

Source: Thrombosis and Haemostasis - April 29, 2024 Category: Hematology Authors: Daisuke Sueta Yugo Yamashita Takeshi Morimoto Ryuki Chatani Yuji Nishimoto Kazuhisa Kaneda Nobutaka Ikeda Yohei Kobayashi Satoshi Ikeda Kitae Kim Moriaki Inoko Toru Takase Shuhei Tsuji Maki Oi Takuma Takeda Kazunori Otsui Jiro Sakamoto Yoshito Ogihara Tak Source Type: research